You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The firm said the new contract will provide funding to support the production of up to 6.7 million COVID-19 antigen and antibody tests per month for the US market.
DARPA program managers said they are developing different testing modalities that are crucially linked in their objective to facilitate more comprehensive and faster testing.
The eight-month contract is for Abbott to provide 50 million BinaxNow SARS-CoV-2 antigen tests with the ordering period ending on Oct. 31.
The administration will expand COVID-19 testing for schools and underserved populations, increase manufacturing of testing supplies, and increase genomic sequencing.
The collaborators are requesting submissions including budget proposals to scale all supporting components of diagnostic test manufacturing.
The test uses isothermal nucleic acid amplification to return results in 20 minutes at the point of care, and demonstrated 98 percent agreement with PCR testing.
Using the Defense Production Act, the companies will bolster manufacturing to provide more than 60 million tests to the US market.
The test was the first OTC at-home test for the coronavirus to receive EUA from the FDA in December. The US will procure 8.5 million tests.
Released by the Pandemic Response Accountability Committee, the report looks at data on test volume, turnaround, cost, and usage at six federal agencies.
The blood test runs on Abbott's i-Stat Alinity platform and returns results within 15 minutes, the company said.